Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RVMD

Revolution Medicines Inc

Dec 01 • 04:00PM ET

24.50

Dollar change +1.17
Percentage change 5.02	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.26	Insider Own	14.30%	Shs Outstand	109.56M	Perf Week	13.53%
Market Cap	2.68B	Forward P/E	-	EPS next Y	-3.39	Insider Trans	-1.24%	Shs Float	93.90M	Perf Month	20.39%
Income	-331.34M	PEG	-	EPS next Q	-0.91	Inst Own	97.09%	Short Float / Ratio	17.30% / 6.55	Perf Quarter	-30.10%
Sales	26.17M	P/S	102.57	EPS this Y	-14.68%	Inst Trans	7.86%	Short Interest	16.25M	Perf Half Y	-4.18%
Book/sh	7.65	P/B	3.20	EPS next Y	4.13%	ROA	-36.61%	Target Price	33.62	Perf Year	3.86%
Cash/sh	7.42	P/C	3.30	EPS next 5Y	-	ROE	-43.63%	52W Range	15.44 - 35.60	Perf YTD	2.85%
Dividend	-	P/FCF	-	EPS past 5Y	-39.15%	ROI	-37.04%	52W High	-31.18%	Beta	1.50
Dividend %	-	Quick Ratio	9.64	Sales past 5Y	24.56%	Gross Margin	65.42%	52W Low	58.68%	ATR	1.44
Employees	246	Current Ratio	9.64	Sales Q/Q	-100.00%	Oper. Margin	-1409.77%	RSI (14)	60.70	Volatility	4.55% 5.59%
Optionable	Yes	Debt/Eq	0.08	EPS Q/Q	-14.66%	Profit Margin	-1266.19%	Rel Volume	0.61	Prev Close	23.33
Shortable	Yes	LT Debt/Eq	0.07	Earnings	Nov 06 AMC	Payout	-	Avg Volume	2.48M	Price	24.50
Recom	1.33	SMA20	14.81%	SMA50	2.37%	SMA200	-4.39%	Volume	1,505,692	Change	5.02%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31
Oct-21-22	Initiated	Oppenheimer	Outperform	$30
May-20-22	Initiated	BofA Securities	Neutral	$24
Mar-01-22	Upgrade	Stifel	Hold → Buy	$36 → $26
Sep-23-21	Initiated	Stifel	Hold	$34
Aug-12-21	Downgrade	Goldman	Buy → Neutral	$49 → $27
May-18-21	Initiated	Goldman	Buy	$49
May-21-20	Initiated	H.C. Wainwright	Buy	$55
Mar-09-20	Initiated	JP Morgan	Neutral	$32
Mar-09-20	Initiated	Guggenheim	Buy	$50
Mar-09-20	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-09-23 09:10AM	Revolution Medicines Completes Acquisition of EQRx (GlobeNewswire) -5.48%
Nov-08-23 11:30AM	Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition (GlobeNewswire)
Nov-07-23 10:14AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:05PM	Loading…
04:05PM	Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-01-23 07:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. (GlobeNewswire)
Oct-31-23 04:15PM	Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 (GlobeNewswire) +7.90%
Oct-23-23 04:06PM	Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining. (Investor's Business Daily) -34.38%
01:48PM	Rebel's Edge - October 20: $TGH, $RVMD, and Astros VS Rangers (TheStreet.com)
12:04PM	Why Revolution Medicines Stock Is Crashing Today (Motley Fool)
10:07AM	Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment (Investor's Business Daily)
Oct-22-23 02:30AM	Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 (GlobeNewswire)
Oct-19-23 07:02AM	Insider Sell: COO Margaret Horn Sells 25,000 Shares of Revolution Medicines Inc (GuruFocus.com)
Oct-16-23 03:19PM	Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 (Investor's Business Daily) +14.08%
09:45AM	Loading…
09:45AM	Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-13-23 02:54PM	Why Shares of Revolution Medicines Were Popping on Friday (Motley Fool) +23.60%
11:50AM	Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting (GlobeNewswire)
Oct-04-23 04:05PM	Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast (GlobeNewswire)
Sep-20-23 07:01AM	Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD) (GuruFocus.com)
Sep-19-23 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor (GlobeNewswire)
Aug-17-23 04:05PM	Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins (GlobeNewswire)
Aug-09-23 02:13PM	Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts (Simply Wall St.)
Aug-08-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-23 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:34PM	EQRx sells to another Alexis Borisy biotech after multiple pivots (American City Business Journals) +20.00%
07:00AM	Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital (GlobeNewswire)
Jul-06-23 09:59AM	Revolution Medicines Insider Ups Holding During Year (Simply Wall St.)
Jun-09-23 08:29AM	We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate (Simply Wall St.)
04:05PM	Loading…
Jun-08-23 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.69%
May-24-23 04:05PM	Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-13-23 08:19AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25% (Simply Wall St.)
May-10-23 06:10AM	Revolution Medicines First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-09-23 09:40AM	Q1 2023 Revolution Medicines Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:25PM	Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:55AM	Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet (Zacks)
May-01-23 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 (GlobeNewswire)
10:01AM	Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-19-23 07:15AM	Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happy (Simply Wall St.)
Apr-13-23 04:05PM	Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference (GlobeNewswire) +7.83%
Apr-06-23 07:00AM	Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-22-23 11:29AM	Revolution Medicines (NASDAQ:RVMD investor three-year losses grow to 18% as the stock sheds US$171m this past week (Simply Wall St.)
Mar-11-23 03:27AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 04:02PM	Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Mar-02-23 09:15PM	Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock (GlobeNewswire) -11.72%
Mar-01-23 04:17PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-27-23 06:25PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-21-23 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023 (GlobeNewswire)
Feb-02-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice (Zacks)
07:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-23 05:31AM	Insiders sitting comfortably on a US$376k profit after buying Revolution Medicines, Inc. (NASDAQ:RVMD) stock worth US$1.0m last year (Simply Wall St.)
Jan-12-23 03:25AM	Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength? (Zacks) +11.12%
Jan-03-23 07:00AM	Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 06:15AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-26-22 08:14AM	We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely (Simply Wall St.)
Dec-19-22 07:00AM	Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor (GlobeNewswire) -9.42%
Dec-08-22 06:19AM	Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration (Benzinga)
Dec-07-22 04:05PM	Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofis Termination of SHP2 Inhibitor Development and Commercialization Collaboration (GlobeNewswire)
Nov-10-22 05:48AM	Institutional owners may consider drastic measures as Revolution Medicines, Inc.'s (NASDAQ:RVMD) recent US$110m drop adds to long-term losses (Simply Wall St.) +13.34%
Nov-09-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-22 05:55PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-02-22 10:01AM	Alpine Immune Sciences, Inc. (ALPN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
09:54AM	Harvard University Stock Portfolio: Top 10 Picks (Insider Monkey)
Nov-01-22 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022 (GlobeNewswire)
Oct-24-22 11:07AM	Who Doesnt Like a Bargain?: Oppenheimer Suggests 2 Stocks to Buy (TipRanks)
Oct-13-22 11:05AM	Loss-making Revolution Medicines (NASDAQ:RVMD) sheds a further US$68m, taking total shareholder losses to 33% over 1 year (Simply Wall St.)
Sep-22-22 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Companys First Mutant-Selective RAS(ON) Inhibitor (GlobeNewswire) +5.44%
Sep-01-22 04:05PM	Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire (GlobeNewswire)
Aug-31-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-22 09:55AM	Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know (Zacks) +8.21%
Aug-10-22 08:35AM	Need To Know: Analysts Are Much More Bullish On Revolution Medicines, Inc. (NASDAQ:RVMD) Revenues (Simply Wall St.)
Aug-09-22 06:15PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Jul-28-22 04:02PM	Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022 (GlobeNewswire)
Jul-22-22 04:02PM	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.30%
Jul-19-22 10:41PM	Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock (GlobeNewswire) +7.71%
04:01PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
07:16AM	Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-13-22 07:00AM	Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors (GlobeNewswire)
Jun-28-22 07:00AM	Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236 (GlobeNewswire) -5.41%
Jun-24-22 09:42AM	Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jun-09-22 04:02PM	Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-11-22 06:22AM	What You Need To Know About The Revolution Medicines, Inc. (NASDAQ:RVMD) Analyst Downgrade Today (Simply Wall St.) -7.66%
May-09-22 05:35PM	Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -11.82%
04:02PM	Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-06-22 09:50AM	Further weakness as Revolution Medicines (NASDAQ:RVMD) drops 4.7% this week, taking one-year losses to 30% (Simply Wall St.) -16.26%
May-05-22 08:05PM	Select Medical (SEM) Beats Q1 Earnings and Revenue Estimates (Zacks) -7.94%
Apr-21-22 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022 (GlobeNewswire) -7.71%
Apr-04-22 07:45AM	Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength? (Zacks) +5.93%
Mar-31-22 08:33AM	7 Stocks That Insiders Are Buying Now. Should You? (InvestorPlace)
Mar-28-22 04:40PM	Strong Insider Buying Puts These 2 Stocks in Focus (TipRanks)
Mar-09-22 07:30AM	Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire) +6.23%
Mar-01-22 04:05PM	Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-28-22 06:05PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cislini Jeff	General Counsel	Nov 20	Sale	21.70	1,500	32,545	38,513	Nov 20 06:24 PM
Horn Margaret A	Chief Operating Officer	Oct 25	Option Exercise	0.54	7,500	4,050	104,460	Oct 25 06:20 PM
GOLDSMITH MARK A	See Remarks	Oct 24	Option Exercise	0.49	35,000	17,150	384,332	Oct 24 07:21 PM
Anders Jack	Chief Financial Officer	Oct 23	Option Exercise	2.98	24,524	72,967	78,191	Oct 23 06:01 PM
Horn Margaret A	Chief Operating Officer	Oct 16	Option Exercise	4.09	25,000	102,250	121,960	Oct 18 04:23 PM
Horn Margaret A	Chief Operating Officer	Oct 16	Sale	33.95	25,000	848,806	96,960	Oct 18 04:23 PM
Kelsey Stephen Michael	See Remarks	Oct 11	Sale	29.05	16,667	484,130	273,721	Oct 13 04:20 PM
Cislini Jeff	General Counsel	Sep 28	Sale	28.20	2,000	56,394	40,013	Oct 02 04:12 PM
GOLDSMITH MARK A	See Remarks	Sep 18	Sale	31.31	8,054	252,175	349,332	Sep 20 04:12 PM
Horn Margaret A	Chief Operating Officer	Sep 18	Sale	31.31	2,514	78,715	96,960	Sep 19 04:17 PM
Kelsey Stephen Michael	See Remarks	Sep 18	Sale	31.31	2,060	64,500	290,388	Sep 20 04:13 PM
Anders Jack	Chief Financial Officer	Sep 18	Sale	31.31	1,427	44,680	53,667	Sep 20 04:11 PM
Cislini Jeff	General Counsel	Sep 18	Sale	31.31	1,214	38,011	42,013	Sep 20 04:11 PM
Horn Margaret A	Chief Operating Officer	Sep 15	Option Exercise	4.09	5,000	20,450	104,474	Sep 19 04:17 PM
Horn Margaret A	Chief Operating Officer	Sep 15	Sale	32.08	5,000	160,408	99,474	Sep 19 04:17 PM
Weber Barbara	Director	Sep 01	Option Exercise	3.80	15,000	57,037	30,825	Sep 06 08:03 PM
Anders Jack	Chief Financial Officer	Sep 01	Option Exercise	2.68	20,000	53,600	75,094	Sep 06 08:02 PM
GOLDSMITH MARK A	See Remarks	Sep 01	Option Exercise	0.77	30,000	23,164	387,386	Sep 06 08:05 PM
GOLDSMITH MARK A	See Remarks	Sep 01	Sale	35.05	30,000	1,051,563	357,386	Sep 06 08:05 PM
Anders Jack	Chief Financial Officer	Sep 01	Sale	35.05	20,000	701,092	55,094	Sep 06 08:02 PM
Weber Barbara	Director	Sep 01	Sale	35.07	15,000	526,000	15,825	Sep 06 08:03 PM
GOLDSMITH MARK A	See Remarks	Sep 01	Sale	35.04	10,000	350,410	35,424	Sep 06 08:05 PM
Horn Margaret A	Chief Operating Officer	Aug 31	Option Exercise	4.09	10,000	40,900	109,474	Sep 01 04:16 PM
Horn Margaret A	Chief Operating Officer	Aug 31	Sale	34.05	10,000	340,458	99,474	Sep 01 04:16 PM
Horn Margaret A	Chief Operating Officer	Aug 15	Option Exercise	4.09	5,000	20,450	104,474	Aug 17 04:17 PM
Horn Margaret A	Chief Operating Officer	Aug 15	Sale	30.53	5,000	152,632	99,474	Aug 17 04:17 PM
Kelsey Stephen Michael	See Remarks	Aug 02	Sale	32.40	16,666	539,978	292,448	Aug 03 04:17 PM
Kelsey Stephen Michael	See Remarks	Aug 01	Sale	29.19	16,666	486,502	309,114	Aug 03 04:17 PM
Cislini Jeff	General Counsel	Jul 31	Sale	26.02	1,500	39,030	43,227	Aug 01 06:23 PM
Kelsey Stephen Michael	See Remarks	Jun 20	Sale	24.89	2,102	52,321	325,780	Jun 22 04:26 PM
Horn Margaret A	Chief Operating Officer	Jun 20	Sale	24.89	2,102	52,321	99,474	Jun 22 04:26 PM
Cislini Jeff	General Counsel	Jun 20	Sale	25.14	1,239	31,148	44,727	Jun 22 04:24 PM
Anders Jack	Chief Financial Officer	Jun 20	Sale	24.89	1,249	31,089	55,094	Jun 22 04:25 PM
Kelsey Stephen Michael	See Remarks	Mar 17	Sale	21.78	1,230	26,789	326,369	Mar 21 08:33 PM
Horn Margaret A	See Remarks	Mar 17	Sale	21.78	1,230	26,789	100,062	Mar 21 08:33 PM
Wang Xiaolin	See Remarks	Mar 17	Sale	21.78	714	15,551	58,813	Mar 21 08:32 PM
Anders Jack	Chief Financial Officer	Mar 17	Sale	21.78	665	14,484	55,233	Mar 21 08:33 PM
Schroeder Thilo	Director	Mar 10	Buy	20.46	100,000	2,045,604	1,553,134	Mar 10 07:00 PM
Schroeder Thilo	Director	Mar 07	Buy	22.00	550,000	12,100,000	1,453,134	Mar 10 07:00 PM
GOLDSMITH MARK A	See Remarks	Feb 22	Option Exercise	0.49	45,000	22,050	251,872	Feb 23 07:33 PM
Kelsey Stephen Michael	See Remarks	Dec 19	Sale	22.94	1,220	27,986	287,599	Dec 21 04:06 PM
Horn Margaret A	See Remarks	Dec 19	Sale	22.94	1,220	27,985	61,292	Dec 21 04:05 PM
Wang Xiaolin	See Remarks	Dec 19	Sale	22.94	708	16,241	30,527	Dec 21 04:07 PM
Anders Jack	Chief Financial Officer	Dec 19	Sale	22.94	658	15,095	29,298	Dec 21 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVMD

Revolution Medicines Inc

Upgrade your FINVIZ experience